We are live on ! Find out more
IBER

Ibere Pharmaceuticals
IBER

Delisted

IBER was delisted on the 1st of March, 2023.

Back to rankings

Fund managers haven’t disclosed any holdings of IBER yet.

IBER Hedge Fund Activity: Q1 2023 in Review

0 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Ibere Pharmaceuticals (IBER) for Q1 2023, worth a combined $0 — down 100% from $126M a quarter earlier.

Sellers outnumbered buyers: 47 funds closed out of IBER and 0 opened new positions — a net loss of 47 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Glazer Capital LLC, exiting entirely with an estimated $13.4M sold.

  • 0 institutional investors held Ibere Pharmaceuticals (IBER) as of Q1 2023, down from 47 in Q4 2022.
  • Funds reported $0 of Ibere Pharmaceuticals stock for Q1 2023, down 100% quarter-over-quarter.
  • 0 funds opened new Ibere Pharmaceuticals positions in Q1 2023 and 47 closed out, a net change of -47 holders.
  • The largest Ibere Pharmaceuticals seller in Q1 2023 was Glazer Capital LLC, an estimated $13.4M sold.

Based on aggregated 13F filings for Q1 2023.